DeFi Development Corp. announced it has resumed accumulating Solana (SOL), surpassing 2.5 million SOL and equivalents by adding over 226,000 SOL since August. The company launched CHAD, a Nasdaq-listed variable rate perpetual preferred stock, creating a new capital market tool alongside common equity. They also established a $300 million at-the-market offering for CHAD to support future SOL accumulation without diluting common shares. Additionally, the company advanced its SOL Boost strategy through staking, validator operations, and ecosystem initiatives, including launching the State of Solana platform and backing governance proposals to strengthen Solana's tokenomics. These moves position DeFi Development Corp. to deepen its exposure to SOL and support Solana's growth.
DeFi Development Corp.'s recent activity includes surpassing 2.5 million SOL in treasury holdings and launching CHAD, a Nasdaq-listed preferred stock. For readers following the broader US stock market, here is Pluang's market snapshot as of Oct 08, 2026 18:43 WIB: out of 150 priced US stocks, 40 rose and 107 fell. Notable movers include United Airlines Holdings Inc (UAL) at USD 107.20 with a -2.70% change and a typical hold time of 46 days, Devon Energy Corp (DVN) at USD 49.15 with a +2.65% change and 92% buy order activity, and Sea Limited (SE) at USD 92.24 with a -2.56% change and 75% sell order activity.
MIND, an AI-native data loss prevention (DLP) platform, was named "Data Loss Prevention Platform of the Year" in the 2026 CyberSecurity Breakthrough Awards. The platform uses advanced AI to discover, detect, and prevent sensitive data leaks across va...
The global Mivan construction market is projected to grow from $3.92 billion in 2025 to $7.05 billion by 2031, at a CAGR of 10.28%. Growth is fueled by demand for rapid mass housing, affordable residential projects, and faster construction enabled by...
RBC Capital has increased its price target for Amgen from $400 to $430, reflecting strong confidence in the biopharmaceutical company's future performance. Amgen's stock has outperformed both the S&P 500 and the broader medical sector recently, suppo...
Tilray Brands reported a wider-than-expected loss of $0.32 per share for Q1 fiscal 2027, missing revenue estimates with $257.1 million, though revenue grew 23% year-over-year. The company achieved record first-quarter gross profit with a 30% gross ma...
UnitedHealth Group is expected to report Q3 earnings of $4.12 per share on $111.3 billion revenue, with investors closely watching medical cost trends and Medicare Advantage membership. The company improved its medical care ratio and operating earnin...
